Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Nat Chem Biol. 2021 Jun;17(6):711-717. doi: 10.1038/s41589-021-00802-w. Epub 2021 May 25.
The zinc-finger transcription factor Helios is critical for maintaining the identity, anergic phenotype and suppressive activity of regulatory T (T) cells. While it is an attractive target to enhance the efficacy of currently approved immunotherapies, no existing approaches can directly modulate Helios activity or abundance. Here, we report the structure-guided development of small molecules that recruit the E3 ubiquitin ligase substrate receptor cereblon to Helios, thereby promoting its degradation. Pharmacological Helios degradation destabilized the anergic phenotype and reduced the suppressive activity of T cells, establishing a route towards Helios-targeting therapeutics. More generally, this study provides a framework for the development of small-molecule degraders for previously unligandable targets by reprogramming E3 ligase substrate specificity.
锌指转录因子 Helios 对于维持调节性 T(T)细胞的身份、无能表型和抑制活性至关重要。虽然它是一个有吸引力的靶点,可以增强目前批准的免疫疗法的疗效,但目前还没有方法可以直接调节 Helios 的活性或丰度。在这里,我们报告了一种结构导向的小分子的开发,这些小分子可以募集 E3 泛素连接酶底物受体 cereblon 到 Helios 上,从而促进其降解。药理学 Helios 降解破坏了无能表型并降低了 T 细胞的抑制活性,为 Helios 靶向治疗开辟了道路。更普遍地说,这项研究通过重新编程 E3 连接酶底物特异性,为以前无法配体化的靶标开发小分子降解剂提供了一个框架。